Clinical Trial Update: Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating bevacizumab combined with allogeneic NK immunotherapy in malignant solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumor

Drugs mentioned

• Allogeneic NK immunotherapy
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: Malignant Solid Tumour | Phase 1, Phase 2 | Status: COMPLETED